CannActuality
Cannabis research for product development
Research Brief · Regulatory Watch
2026 divided federal marijuana policy into a finished piece and an unfinished one. The finished piece: on April 23, 2026, DEA issued a final order under 21 U.S.C. § 811(d)(1) placing three categories into Schedule III — marijuana within an FDA-approved product; marijuana cultivated and sold under qualifying state medical marijuana licenses; and covered extracts and naturally derived delta-9 THC tied to those channels. The order creates a federal registration pathway (21 C.F.R. § 1301.13(k)) with an expedited six-month review in which a qualifying state medical license is treated as conclusive evidence of authorization. DEA stated expressly that marijuana outside those channels — including all state adult-use activity — remains a Schedule I controlled substance, and that hemp and synthetically derived THC fall outside the order. Whether registered medical operators are also relieved of Internal Revenue Code § 280E deduction limits is flagged as unresolved by the order's own text; DEA and Treasury signals point in different directions, and operators are being advised to take tax counsel before booking the benefit.
The unfinished piece: the general rulemaking to move all marijuana from Schedule I to Schedule III. Following Executive Order 14370 (December 2025) directing DOJ to complete the process expeditiously, DEA held merits hearings from June 29 to July 15, 2026. On September 29, 2026, Chief Administrative Law Judge Derek C. Julius stayed the proceedings while he considers admitting a September 23, 2026 GAO report (GAO-26-108623) on federal drug-scheduling process into the record. The government's response was due October 13, 2026; the ALJ must still decide on admission and briefing before any recommendation issues, and no final-rule date exists. A stay is a pause, not a ruling against rescheduling — but roadmaps that assume a completion date are assuming something no source supports.
Section 781 of Public Law 119-37 (signed November 12, 2025) rewrote the federal definition of hemp. Three changes do the work: the 0.3% plant threshold now counts total THC, including THCA; cannabinoids that are synthesized or cannot be naturally produced by the plant are excluded from hemp entirely; and finished hemp products are capped at 0.4 mg of total THC per container — a level no intoxicating gummy, beverage, or flower product on the market meets. Products outside the new definition are marijuana under the Controlled Substances Act.
The effective dates split in two. Under the original law, everything landed November 12, 2026. The Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103, signed September 2, 2026) moved the main body of the redefinition to December 11, 2026, while the exclusion for non-naturally-producible cannabinoids still takes effect November 12, 2026. As of September 28, 2026, FDA had not yet published the list of naturally occurring and THC-class cannabinoids the law directed it to issue. Bills to delay, repeal, or replace the redefinition with a regulatory framework were pending in committee as of October 2026 — none had passed. State-licensed medical and adult-use programs are not changed by the hemp law; what ends is the unlicensed federal channel.
California moved first. AB 8 (signed October 2, 2025) phases hemp-derived cannabinoids into the licensed cannabis framework. Interim provisions effective January 1, 2026 prohibit intoxicating hemp sales outside licensed channels, ban hemp flower and pre-rolls outright, extend the state's 15% cannabis excise tax to hemp products, and bar tobacco retailers from selling cannabis or hemp products. On January 1, 2028, full integration takes effect: intoxicating hemp products must move through state-licensed channels with full MAUCRSA compliance — licensing, testing, track-and-trace, and age verification. Separately, the cannabis excise tax rate sits at 15% from October 1, 2025 through June 30, 2028 (set by AB 564), giving licensed operators a stable — if still substantial — tax assumption for 2026–2027 planning. The Governor's 2026-27 budget funds DCC and CDTFA enforcement of the hemp integration, which is the practical signal that the interim rules are being policed, not parked.
This brief is regulatory reporting and education for licensed cannabis vendors, current as of its publication date. It is not legal advice; cannabis law is changing on the timelines described above, and product decisions with legal exposure should be reviewed with qualified counsel in the relevant jurisdiction. CannActuality makes no health or benefit claims about cannabis products. Intended for adults 21+.